Kineta is at the forefront of developing next-generation immunotherapies aimed at addressing the significant challenges faced by current cancer treatments. The company focuses on enhancing the efficacy of checkpoint inhibitor (CPI) therapies, which have shown promise in improving patient outcomes but still leave a large percentage of patients—70% to 80%—as non-responders. Kineta's innovative approach seeks to reprogram the immune system to effectively target cancer cells by integrating both innate and adaptive immune responses. Their drug programs are specifically designed to tackle issues such as immuno-suppression, exhausted T-cells, and poor tumor immunogenicity, which are critical barriers to successful cancer treatment.

Kineta's pipeline includes the development of fully human antibodies that specifically target mechanisms of cancer immune resistance. One of their key drug candidates, KVA12123, is designed to block the VISTA pathway, which is implicated in immune suppression in advanced solid tumors. The company is actively advancing its clinical trials, with anticipated milestones that include safety and efficacy data for monotherapy and initial combination therapy results. By focusing on these innovative therapies, Kineta aims to significantly improve survival rates and long-term outcomes for cancer patients, ultimately transforming the landscape of cancer treatment.

United States

Kineta is a clinical stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives.

Cancer

Kineta

Parkinson's disease

YTX-7739 is Yumanity Therapeutics’ proprietary lead investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target that plays an important and previously unrecognized role in the neurotoxicity caused by the a-synuclein protein, a major driver of Parkinson’s disease and related neurodegenerative disorders. Misfolding and aggregation of the a-synuclein protein triggers a cascade of events, ultimately resulting in neurotoxicity and the subsequent disorders in movement and cognition that affect patients living with these diseases. YTX-7739 has been shown to inhibit many of the key aspects of a-synuclein toxicity and the company is assessing its potential utility in Parkinson’s disease.
<a href="https://yumanity.gcs-web.com/static-files/1db6be2c-8c2a-406a-8ab6-fb990ee439db">Source</a>

YTX-7739

Solid tumor/s

KVA12123 is a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody infusion drug being evaluated in a Phase 1/2 clinical trial for patients with advanced solid tumors. Competitive therapies targeting VISTA have demonstrated either poor monotherapy anti-tumor activity in preclinical models or induction of cytokine release syndrome (CRS) in human clinical trials. Through the combination of unique epitope binding and an optimized IgG1 Fc region, KVA12123 demonstrates strong monotherapy tumor growth inhibition in preclinical models without evidence of CRS in clinical trial participants. KVA12123 has been shown to de-risk the VISTA target and provides a novel approach to address immune suppression in the TME with a mechanism of action that is differentiated and complementary with T cell focused therapies. KVA12123 may be an effective immunotherapy for many types of cancer including non-small cell lung (NSCLC), colorectal, renal cell carcinoma, head and neck, and ovarian cancer.

Kineta

Company Details